119 related articles for article (PubMed ID: 2617702)
1. Exacerbation of metastatic disease shortly after administration of tamoxifen in ER negative advanced breast carcinoma. A case report.
Cocconi G; Boni C; Naldi N; Nizzoli R; Bozzetti C
Tumori; 1989 Dec; 75(6):566-9. PubMed ID: 2617702
[TBL] [Abstract][Full Text] [Related]
2. Oestrogen receptors and the response of metastatic breast cancer to aminoglutethimide or tamoxifen.
Holdaway IM
Aust N Z J Surg; 1981 Aug; 51(4):345-7. PubMed ID: 6944051
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
Allred DC; Anderson SJ; Paik S; Wickerham DL; Nagtegaal ID; Swain SM; Mamounas EP; Julian TB; Geyer CE; Costantino JP; Land SR; Wolmark N
J Clin Oncol; 2012 Apr; 30(12):1268-73. PubMed ID: 22393101
[TBL] [Abstract][Full Text] [Related]
4. [A case of advanced breast cancer with multiple organ metastases successfully treated by tamoxifen].
Shiba E; Kobayashi T; Takeda T; Miya A; Kawano I; Takai S; Mori T
Gan To Kagaku Ryoho; 1992 Nov; 19(13):2255-8. PubMed ID: 1444494
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.
Ravdin PM; Green S; Dorr TM; McGuire WL; Fabian C; Pugh RP; Carter RD; Rivkin SE; Borst JR; Belt RJ
J Clin Oncol; 1992 Aug; 10(8):1284-91. PubMed ID: 1634918
[TBL] [Abstract][Full Text] [Related]
6. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group.
Fernö M; Stål O; Baldetorp B; Hatschek T; Källström AC; Malmström P; Nordenskjöld B; Rydën S
Breast Cancer Res Treat; 2000 Jan; 59(1):69-76. PubMed ID: 10752681
[TBL] [Abstract][Full Text] [Related]
7. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
8. Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen.
Bonomi P; Gale M; Von Roenn J; Anderson K; Johnson P; Wolter J; Economou S
Semin Oncol; 1988 Apr; 15(2 Suppl 1):26-33. PubMed ID: 3368797
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK
Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of breast cancer based on its specific biological behavior].
Tominaga T
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2718-25. PubMed ID: 3753020
[TBL] [Abstract][Full Text] [Related]
11. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.
Johnston SR; Saccani-Jotti G; Smith IE; Salter J; Newby J; Coppen M; Ebbs SR; Dowsett M
Cancer Res; 1995 Aug; 55(15):3331-8. PubMed ID: 7614468
[TBL] [Abstract][Full Text] [Related]
12. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.
Howell A; Robertson JF; Abram P; Lichinitser MR; Elledge R; Bajetta E; Watanabe T; Morris C; Webster A; Dimery I; Osborne CK
J Clin Oncol; 2004 May; 22(9):1605-13. PubMed ID: 15117982
[TBL] [Abstract][Full Text] [Related]
13. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen.
Encarnación CA; Ciocca DR; McGuire WL; Clark GM; Fuqua SA; Osborne CK
Breast Cancer Res Treat; 1993; 26(3):237-46. PubMed ID: 8251648
[TBL] [Abstract][Full Text] [Related]
14. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
[TBL] [Abstract][Full Text] [Related]
15. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
Morrissey JJ; Raney S
Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.
Robertson JF; Nicholson RI; Bundred NJ; Anderson E; Rayter Z; Dowsett M; Fox JN; Gee JM; Webster A; Wakeling AE; Morris C; Dixon M
Cancer Res; 2001 Sep; 61(18):6739-46. PubMed ID: 11559545
[TBL] [Abstract][Full Text] [Related]
17. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
[TBL] [Abstract][Full Text] [Related]
18. Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer.
Namer M; Lalanne C; Baulieu EE
Cancer Res; 1980 May; 40(5):1750-2. PubMed ID: 7371003
[TBL] [Abstract][Full Text] [Related]
19. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
[TBL] [Abstract][Full Text] [Related]
20. The correlation of estrogen and progesterone receptor levels with response to chemotherapy for advanced carcinoma of the breast.
Paone JF; Abeloff MD; Ettinger DS; Arnold EA; Baker RR
Surg Gynecol Obstet; 1981 Jan; 152(1):70-4. PubMed ID: 7455895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
